University: We Make Lives Better

Barshop Institute for Longevity and Aging Studies

Veronica Galvan, Ph.D.


Veronica Galvan, Ph.D.

Associate Professor
Department of Cellular and Integrative Physiology
Barshop Institute for Longevity and Aging Studies
University of Texas Health Science Center at San Antonio
Phone: 210-562-5029

Galvan Lab Website



Alzheimer’s disease (AD) is an incapacitating age-related neurodegenerative disorder characterized by memory loss and progressive deterioration of cognitive function. AD and AD-related dementia accounts for more than 60% of all dementia cases. Current treatment options for AD are limited, and only temporarily palliative.  Because of its high prevalence and the continuing increase of the aged population, AD is a major health problem with serious negative consequences for affected individuals and their families, as well as local and worldwide economies.

Our research is focused on the identification of molecular and biochemical alterations that cause AD.  By understanding how AD is triggered and how it develops, we can devise ways to slow or prevent the disease. We use genetic manipulations in mouse models, behavioral, immunohistochemical and biochemical approaches, in vivo brain optical and functional imaging, in vivo brain blood flow measures, and cellular and molecular biology tools to understand the initiating molecular events in AD, determine the effects of potential drug candidate molecules, and define the mechanisms involved. 

Amyloid-ß regulation. Late stage AD is characterized by brain lesions that include amyloid plaques enriched in amyloid-beta (Aß) and neurofibrillary tangles containing misfolded forms of the microtubule-binding protein tau. Understanding the mechanisms by which Aß and tau are dysregulated and become pathogenic is needed to formulate strategies to prevent or treat AD.  Using surrogate models of AD, we have identified a key role of the mammalian target of rapamycin (TOR), a major regulator of metabolism and organismal aging, in the control of brain Aß levels through the modulation of autophagy.

Reduced cerebral blood flow and blood-brain barrier breakdown in AD: The earliest stages of AD are marked by decreased cerebral blood flow and blood-brain barrier (BBB) breakdown.  Understanding the causes for diminished cerebral blood flow and BBB collapse in AD will allow us to devise methods to slow or block progression of the disease at its earliest stage. We recently identified TOR-dependent mechanisms that drive the decrease in brain blood flow in AD models through the inhibition of endothelial nitric oxide synthase (eNOS) and the collapse of BBB through downregulation of the key tight junction scaffold protein junctional adhesion protein A (JAM-A).  Our studies show that preservation of endothelium-dependent vasodilation is required for the restoration of cerebral blood flow in models of AD, and that the resulting increase in brain circulation enables the continuous elimination of Aß from brain.  mTOR is thus involved in the control of net Aß levels through autophagy in neurons, and in the regulation of clearance of Aß from brain through the cerebral vasculature. Drugs that attenuate mTOR thus establish a feedforward loop that reduces net Aß levels in brain by simultaneously reducing its production and increasing its elimination from brain.

Microvascular tau in AD and other tauopathies:  We recently showed that prefilamentous aggregates of hyper-phosphorylated tau (tau oligomers) accumulate in brain microvessels of AD and of progressive supranuclear palsy (PSP) patients, suggesting that, like Aß, extracellular tau may propagate to non-neuronal cell types and thus contribute to brain microvascular dysfunction in AD and other neurodegenerations associated with tauopathy.  We are currently exploring the co-occurrence of misfolded tau and Aß in cerebrovasculature of AD and PSP, and the propagation of misfolded tau oligomers to non-neuronal cell types in AD brain.

So far, our research has led us to discover a key role of TOR in the initiation of neuronal and brain vascular dysfunction in AD through pathways involving Aß and tau.  Because TOR controls key aspects of metabolism in most cell types we hypothesize that TOR may be involved in several cell-specific complex disease mechanisms driving neurodegeneration in AD. Thus, to define the role of TOR in AD, we study mechanisms by which pathways centered on TOR but mediating distinct processes in different brain compartments such as neurons and brain vascular cells synergize to precipitate loss of function.  Based on our findings, we are currently engaged in safety studies of rapamycin, and in drug screening/drug discovery efforts in a search for (a) compounds that regulate the activity of the TOR pathway and (b) compounds that regulate JAM-A levels, that may be used to slow or treat AD and potentially other dementias. 


Cerebral Microvascular Accumulation of Tau Oligomers in Alzheimer's Disease and Related Tauopathies. Castillo-Carranza DL, Nilson AN, Van Skike CE, Jahrling JB, Patel K, Garach P, Gerson JE, Sengupta U, Abisambra J, Nelson P, Troncoso J, Ungvari Z, Galvan V, Kayed R. Aging Dis. 2017 May 2;8(3):257-266. doi: 10.14336/AD.2017.0112. eCollection 2017 May. PMID: 28580182

mTOR drives cerebral blood flow and memory deficits in LDLR-/- mice modeling atherosclerosis and vascular cognitive impairment. Jahrling JB, Lin AL, DeRosa N, Hussong SA, Van Skike CE, Girotti M, Javors M, Zhao Q, Maslin LA, Asmis R, Galvan V. J Cereb Blood Flow Metab. 2017 Jan 1:271678X17705973. doi: 10.1177/0271678X17705973. [Epub ahead of print] PMID: 28511572

Vascular mTOR-dependent mechanisms linking the control of aging to Alzheimer's disease. Galvan V, Hart MJ. Biochim Biophys Acta. 2016 May;1862(5):992-1007. doi: 10.1016/j.bbadis.2015.11.010. Epub 2015 Nov 27. PMID: 26639036

Chronic rapamycin restores brain vascular integrity and function through NO synthase activation and improves memory in symptomatic mice modeling Alzheimer's disease. Lin AL, Zheng W, Halloran JJ, Burbank RR, Hussong SA, Hart MJ, Javors M, Shih YY, Muir E, Solano Fonseca R, Strong R, Richardson AG, Lechleiter JD, Fox PT, Galvan V. J Cereb Blood Flow Metab. 2013 Sep;33(9):1412-21. doi: 10.1038/jcbfm.2013.82. Epub 2013 Jun 26. PMID: 23801246

Chronic inhibition of mammalian target of rapamycin by rapamycin modulates cognitive and non-cognitive components of behavior throughout lifespan in mice. Halloran J, Hussong SA, Burbank R, Podlutskaya N, Fischer KE, Sloane LB, Austad SN, Strong R, Richardson A, Hart MJ, Galvan V. Neuroscience. 2012 Oct 25;223:102-13. doi: 10.1016/j.neuroscience.2012.06.054. Epub 2012 Jun 28. Erratum in: Neuroscience. 2015 Oct 15;306():151. PMID: 22750207

Over-expression of heat shock factor 1 phenocopies the effect of chronic inhibition of TOR by rapamycin and is sufficient to ameliorate Alzheimer's-like deficits in mice modeling the disease. Pierce A, Podlutskaya N, Halloran JJ, Hussong SA, Lin PY, Burbank R, Hart MJ, Galvan V. J Neurochem. 2013 Mar;124(6):880-93. doi: 10.1111/jnc.12080. Epub 2012 Dec 26. PMID: 23121022

Inhibition of mTOR by rapamycin abolishes cognitive deficits and reduces amyloid-beta levels in a mouse model of Alzheimer's disease. Spilman P, Podlutskaya N, Hart MJ, Debnath J, Gorostiza O, Bredesen D, Richardson A, Strong R, Galvan V. PLoS One. 2010 Apr 1;5(4):e9979. doi: 10.1371/journal.pone.0009979. Erratum in: PLoS One. 2011;6(11). doi:10.1371/annotatio /05c1b976-7eab-4154-808d-0526e604b8eb.  PMID: 20376313


BarshopINSTITUTElogo _Converted_
The Sam and Ann Barshop Institute for Longevity and Aging Studies

15355 Lambda Drive
San Antonio, Texas  78245
P: 210-562-6140 F: 210-562-6150

Copyright © 2018
UT Health San Antonio

The University of Texas Health Science Center
Accessibility | Public/Personal Information | Site Information | Web Privacy

Links from web sites affiliated with The University of Texas Health Science Center's web site ( to other web sites do not constitute or imply university endorsement of those sites, their content, or products and services associated with those sites.

Site Developed by Toolbox Studios, Inc.